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Abstract
Changes in the distribution of L-adrenoceptors (LARs) in the plasma membrane and the light vesicle fractions of rat liver
during different phases of sepsis were studied using [3H]dihydroalprenolol binding and photoaffinity labeling with
[125I]iodocyanopindolol diazirine. Sepsis was induced by cecal ligation and puncture (CLP). Septic rats exhibit an initial
hypermetabolic (hyperglycemic) phase (9 h after CLP; early sepsis) followed by a hypometabolic (hypoglycemic) phase (18 h
after CLP; late sepsis). The radioligand studies show that in the plasma membranes, the density of LARs was decreased by
28^32% and 46^69% during the early and the late phases, respectively, of sepsis. In the light vesicles, the density of LARs was
increased by 25^30% and 30^35% during the early and the late phases, respectively, of sepsis. The total number of the
receptor binding sites (the sum of that in plasma membrane plus light vesicle) was decreased by 11^12% and 21^35% during
the early and the late phases, respectively, of sepsis. These results indicate that LARs were progressively internalized from
surface membranes to the intracellular sites and, furthermore, they were underexpressed in the rat liver during the
progression of sepsis. Since hepatic glucose metabolism is known to be regulated by catecholamines, in part, through LAR
mediation, an internalization/underexpression of hepatic LARs may play a role in the altered glucose homeostasis during
sepsis, particularly in the late hypometabolic phase of sepsis. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Sepsis and septic shock are often complicated by
altered hepatic function and glucose dyshomeostasis
which are characterized by a two-phase alteration
consisting of an initial hypermetabolic (hyperglyce-
mic) phase followed by a progressive hypometabolic
(hypoglycemic) phase [1]. The ultimate hypoglycemia
is of su⁄cient magnitude to cause death [1,2]. Meta-
bolic pathways such as glycogenesis, glycogenolysis,
and gluconeogenesis that control the homeostatic
level of glucose are regulated by sympathetic-cate-
cholamine system through Ca2-linked K1-adreno-
ceptor (K1AR) and cAMP-linked L2-adrenoceptor
(L2AR) mediation [3,4]. The exact contribution of
the two types of receptor on the regulation of glucose
homeostasis di¡ers with species [5,6]. Although glu-
cose metabolic pathways in the rat liver are predom-
inantly controlled by K1AR mediation, a ‘coopera-
tive e¡ect and interaction’ between KARs and LARs
commonly modulates glycogenolytic responses [7^9].
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A shift from K1AR to L2AR responsiveness is de-
monstrable in the rat liver under various pathological
conditions including preneoplasia [10], hypothyroid-
ism [11], glucocorticoid de¢ciency [12], liver regener-
ation [13], cholestasis [14], and endotoxicosis [15].
Although LARs have been reported to be downregu-
lated in the rat liver after trauma and hemorrhagic
shock [16], little is known in regard to alterations of
LARs in the rat liver during the initial hyperglycemic
and the subsequent hypoglycemic phases of sepsis.
Recent advances in the studies of membrane surface
receptors have indicated that LARs are actively regu-
lated by processes such as synthesis, internalization,
recycling, and degradation, in which the receptors
exist in several subcellular compartments including
plasma membrane and an intracellular site, the light
vesicle [17^19]. Accordingly, the present study was
undertaken to investigate changes in the intracellular
distribution of LARs between the plasma membrane
and the light vesicle fractions in the rat liver during
the progression of sepsis in an attempt to understand
the pathogenesis of the altered hepatic glucose me-
tabolism during the progression of sepsis.
2. Materials and methods
2.1. Materials
(3)-[4,6-propyl-3H]Dihydroalprenolol (90 Ci/
mmol) and (3)-[125I]iodocyanopindolol diazirine
(2000 Ci/mmol) were purchased from Amersham
and DuPont-New England Nuclear, respectively.
(3)-Alprenolol, (3)-isoproterenol, 5P-guanylylimido-
diphosphate, soybean trypsin inhibitor, aprotinin,
pepstatin A, leupeptin, sodium dodecyl sulfate, phen-
ylmethylsulfonyl £uoride and EDTA were products
of Sigma Chemical. Other chemicals and reagents
were of analytical grade.
2.2. Animal model
All animal experiments in this study were per-
formed with the approval of the Animal Care Com-
mittee of Saint Louis University School of Medicine,
and in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory
Animals. Male Sprague-Dawley rats weighing from
270 to 320 g were used. All animals were fasted over-
night with free access to water. They were divided
into three groups: control, early sepsis, and late sep-
sis. Sepsis was induced by cecal ligation and puncture
(CLP) as described by Wichterman et al. [20] with
minor modi¢cation. Under halothane anesthesia, a
laparotomy was performed and the cecum was li-
gated with a 3-0 silk ligature and punctured twice
with an 18-gauge needle. The cecum was then re-
turned to the peritoneal cavity and the abdomen
was closed in two layers. Control rats were sham-
operated (a laparotomy was performed and the ce-
cum was manipulated but neither ligated nor punc-
tured). All animals were resuscitated with 4 ml/100 g
body weight of normal saline at the completion of
surgery and also at 7 h post surgery. Animals were
fasted but had free access to water after operative
procedures. Livers were removed from septic and
control animals 9 or 18 h post operation under chlor-
alose and urethane anesthesia and were then used for
the preparation of plasma membranes and light
vesicles as described below. Early and late sepsis re-
fer to those animals sacri¢ced at 9 and 18 h, after
CLP. The mortality rates were 0% (0/18) for control,
10% (2/20) for early sepsis, and 22% (5/23) for late
sepsis. Preliminary experiments indicate that in septic
rats, plasma glucose concentration was elevated by
20% (P6 0.01) during the early phase while it was
decreased by 69% (P6 0.01) during the late phase of
sepsis (7.0 þ 0.06, 8.5 þ 0.15, and 2.2 þ 0.15 mM for
control, early sepsis, and late sepsis, respectively).
2.3. Preparation of hepatic plasma membranes and
light vesicles
Rat liver plasma membranes and light vesicles
were prepared according to a procedure previously
described by us [21]. Brie£y, livers removed from
control and septic animals were weighed, frozen,
and pulverized. The powdered tissues were homogen-
ized in 5 vols. of bu¡er A (10 mM Tris-HCl, pH 7.6,
0.25 M sucrose, 0.l mM penylmethylsulfonyl £uo-
ride) and the homogenates centrifuged at 17 500Ug
for 20 min. The resulting pellets were homogenized
again in bu¡er A and centrifuged at 2500Ug for
20 min. The 2500Ug pellets were rehomogenized
and recentrifuged. The supernatants from 2500Ug
centrifugation were pooled and centrifuged at
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79 700Ug for 40 min. The 79 700Ug supernatants
were centrifuged at 205 800Ug for 70 min and the
resulting pellets used as a light vesicle preparation
after resuspension in bu¡er A. The 79 700Ug pellets
were resuspended in 80% (w/w) sucrose to give a ¢nal
concentration of 62% sucrose. Ten milliliters of this
suspension was layered at the bottom of a discontin-
uous sucrose gradient consisting of 4 ml of 54%, 6 ml
of 48%, 4 ml of 43%, and 4 ml of 8% sucrose. The
gradients were then centrifuged at 205 800Ug for
70 min. Fractions at 8:43% and 43:48% sucrose in-
terfaces were collected, pooled, diluted with bu¡er B
(10 mM NaHCO3, 5 mM histidine, pH 7.4), and
centrifuged at 162 600Ug for 40 min. The resulting
pellets were suspended in bu¡er A and subjected to
sucrose gradient centrifugation one more time. Frac-
tions at 8:43% and 43:48% sucrose interfaces of the
second sucrose gradient centrifugation were pooled,
pelleted, resuspended in bu¡er A, and then used as a
plasma membrane preparation. The plasma mem-
brane and light vesicle preparations were stored at
380‡C and the receptor binding assays performed
within 2 weeks. The entire procedure was performed
at 4‡C unless otherwise stated. The protein content
of the liver membranes was determined by the meth-
od of Lowry et al. [22]. The plasma membrane frac-
tion obtained exhibits a ¢vefold enrichment while the
light vesicle fraction obtained shows no enrichment
in the activity of its marker enzyme, the 5P-nucleoti-
dase. The glucose 6-phosphatase (a marker enzyme
for endoplasmic reticulum) activities were not en-
riched in plasma membranes or in light vesicles.
These data indicate that the plasma membrane and
light vesicle fractions obtained as described above
were highly puri¢ed and minimally contaminated
with endoplasmic reticulum.
2.4. [3H]Dihydroalprenolol binding to liver
membranes
LAR binding assays were carried out using (3)-
[3H]dihydroalprenolol ([3H]DHA) as a radioligand
based on a procedure previously described by us
[23^25]. The standard assay mixture in a ¢nal volume
of 0.2 ml contained 10 mM MgCl2, 50 mM Tris-HCl
(pH 7.4), 10 nM [3H]DHA (90 Ci/mmol), and 0 or
10 WM unlabeled (3)-alprenolol. For Scatchard plot
analysis, di¡erent concentrations of [3H]DHA rang-
ing from 2 to 30 nM were used. For agonist displace-
ment studies, (3)-isoproterenol (108^1033 M) and
5P-guanylylimidodiphosphate (Gpp[NH]p, 0.1 mM)
were included in the standard assay mixture. The
mixture was preincubated at 37‡C for 2 min. The
binding assay was subsequently initiated by the ad-
dition of plasma membranes (40 Wg protein) or light
vesicles (80 Wg protein) and allowed to proceed for
20 min at 37‡C. At the end of each incubation, the
reaction mixture was diluted with 4 ml of ice-cold
washing bu¡er (10 mM MgCl2, 50 mM Tris-HCl,
pH 7.4) and ¢ltered immediately through a 0.45 Wm
glass ¢ber ¢lter paper (Baxter Healthcare) under suc-
tion. The ¢lter paper was washed three times with
5 ml of washing bu¡er and dried, and the radioac-
tivity was then determined with a liquid scintillation
counter. The speci¢c binding was de¢ned as the
bound radioactivity displaceable by 10 WM (3)-al-
prenolol.
2.5. Photoa⁄nity labeling of liver L-adrenoceptors by
[125I]iodocyanopindolol diazirine, sodium dodecyl
sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and autoradiography
Photoa⁄nity labeling of LARs of hepatic plasma
membranes and light vesicles was performed based
on a procedure described in our previous report [25].
Hepatic plasma membranes (100 Wg protein) or light
vesicles (150 Wg protein) were incubated in the dark
in a total volume of 0.5 ml of N2-saturated resuspen-
sion bu¡er (20 mM Tris-HCl, pH 7.4, 5 mM EDTA,
2 mM MgCl2, 0.25 M sucrose, 5 Wg soybean trypsin
inhibitor, 2.5 Wg leupeptin, 0.5 Wg aprotinin, and
0.5 Wg pepstatin A) containing 1.5 nM
[125I]iodocyanopindolol diazirine ([125I]ICYP diazir-
ine; 2000 Ci/mmol) and 0 or 10 WM unlabeled (3)-
alprenolol. After 6 h labeling the membranes were
photolyzed for 60 min at 4‡C. After 6 ml of resus-
pension bu¡er were added to each tube, all photo-
lyzed samples were centrifuged at 162 600Ug for
40 min and the resulting pellets washed one more
time. The ¢nal pellets were dissolved in 0.5 ml of
gel sample bu¡er (50 mM Tris-HCl, pH 6.9, 2%
SDS, 10% glycerol, and 0.002% bromophenol blue),
and the samples were allowed to stand at room tem-
perature for 45 min. The covalent incorporation of
radioligand was analyzed by SDS-PAGE (10% acryl-
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amide gel), and the electrophoresis performed [25].
Autoradiography was performed by placing dried
gel in contact with Kodak XAR-5 ¢lm for 3 days
at 380‡C. For the quanti¢cation of 125I-labeling,
the dried gel tracks were cut into 3 mm slices and
the radioactivity was determined by liquid scintilla-
tion counting.
2.6. Statistical analysis
The statistical analysis of the data was performed
using one-way ANOVA followed by Student-New-
man-Keuls tests. A P-value of less than 0.05 was
accepted as statistically signi¢cant.
3. Results
Figs. 1 and 2 show the e¡ects of sepsis on the
dynamics of LARs in the rat liver plasma membranes
and light vesicles based on [3H]DHA binding studies.
The Scatchard analyses for [3H]DHA binding for
both plasma membranes and light vesicles indicate
a single component binding characteristic (data not
shown). As shown in Fig. 1, the Bmax (maximal bind-
ing capacity determined by Scatchard plot) for
[3H]DHA binding in plasma membranes was de-
creased by 32% (P6 0.01) and 69% (P6 0.01) during
the early and the late phases of sepsis, respectively
(228 þ 7, 156 þ 5, and 70 þ 2 fmol/mg for control,
early sepsis, and late sepsis, respectively) (Fig. 1A).
The a⁄nity (the reciprocal of the dissociation con-
stant (Kd)) for [3H]DHA binding in plasma mem-
branes remained una¡ected during the early and
the late phases of sepsis (Kd values in nM:
5.3 þ 0.3, 4.4 þ 0.2, and 4.9 þ 0.6 for control, early
sepsis, and late sepsis, respectively) (Fig. 1B). As
shown in Fig. 2, the Bmax for [3H]DHA binding in
the light vesicle fraction was increased by 25%
(P6 0.01) and 30% (P6 0.01) during the early and
the late phases of sepsis, respectively (122 þ 7,
152 þ 7, and 158 þ 6 fmol/mg for control, early sepsis,
and late sepsis, respectively) (Fig. 2A). The a⁄nity
for [3H]DHA binding in light vesicles was unaltered
during the early and the late phases of sepsis (Kd
values in nM: 6.1 þ 0.4, 5.8 þ 0.3 and 5.4 þ 0.4 for
control, early sepsis, and late sepsis, respectively)
(Fig. 2B). The ¢ndings that the Bmax for [3H]DHA
binding was decreased progressively in the plasma
membranes during the early and the late phases of
sepsis and that the decreases were paralleled with the
increases in the Bmax in the light vesicles, suggest that
LARs in the rat liver were progressively internalized
from surface membranes to the intracellular sites
Fig. 1. E¡ects of sepsis on the density of L-adrenoceptors in
the plasma membranes isolated from rat livers based on
[3H]DHA binding studies. [3H]DHA binding was performed as
described in Section 2. (A) Maximal binding capacity (Vmax);
(B) Kd values. Vertical bars indicate S.E.M. Numbers of experi-
ments are shown in parentheses in each column. ES, early sep-
sis ; LS, late sepsis. Early and late sepsis refer to measurements
performed at 9 and 18 h, respectively, after cecal ligation and
puncture.
Table 1
Modulation of L-adrenoceptors by Gpp(NH)p in the plasma
membranes and light vesicles prepared from control and septic
rat livers
IC50 values (M)
Plasma membranes Light vesicles
Control
3Gpp(NH)p 6.7U1038 4.0U1037
+Gpp(NH)p 3.2U1037 4.4U1037
Early sepsis
3Gpp(NH)p 3.0U1037 4.1U1037
+Gpp(NH)p 3.3U1037 4.4U1037
Late sepsis
3Gpp(NH)p 1.5U1037 5.0U1037
+Gpp(NH)p 1.7U1037 5.2U1037
Values are mean of six experiments. IC50 values were obtained
from isoproterenol-competed [3H]DHA binding studies in the
absence or presence of 0.1 mM Gpp(NH)p (guanylylimidodi-
phosphate). Early and late sepsis refer to those animals sacri-
¢ced at 9 and 18 h, respectively, after cecal ligation and punc-
ture.
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during the early hyperglycemic and the subsequent
hypoglycemic phases of sepsis.
Table 1 illustrates the modulation of LARs by the
guanine nucleotide, Gpp(NH)p, in plasma membrane
and light vesicle fractions prepared from control and
septic rat livers. Isoproterenol, a potent LAR agonist,
competes e¡ectively with [3H]DHA binding in plas-
ma membrane and light vesicle fractions in all groups
of experiments. In plasma membranes prepared from
control rats, addition of Gpp(NH)p shifted the ago-
nist competition curve to the right, with an increase
in the IC50 (the concentration of unlabeled ligand
required to inhibit 50% of the binding of the labeled
ligand) value from 6.7U1038 to 3.2U1037 M. These
data indicate that in plasma membranes prepared
from control rat liver, agonists recognize two classes
Table 2
Changes in the total number of L-adrenoceptor binding sites in
the rat liver during di¡erent phases of sepsis
[3H]DHA binding
(fmol/mg protein)
[125I]ICYP diazirine
incorporation
(fmol/mg protein)
Control 350 þ 8 66 þ 4
Early sepsis 308 þ 12** 59 þ 3*
Late sepsis 228 þ 10** 52 þ 3**
Values are means þ S.E., n = 6 experiments. *P6 0.05,
**P6 0.01 compared with the control.
Fig. 4. E¡ects of sepsis on the photoa⁄nity labeling of L-adre-
noceptors in rat liver light vesicles with [125I]ICYP diazirine fol-
lowed by SDS-PAGE. A depicts a representative autoradio-
gram. Light vesicles were reacted with [125I]ICYP diazirine in
the absence (lanes 1, 3, and 5) or presence (lances 2, 4, and 6)
of 10 WM alprenolol as described in Section 2. B shows quanti-
tative analyses of the incorporation of [125I]ICYP diazirine into
64 kDa peptides. For symbols, abbreviations, and other details,
see the legend to Fig. 3.
Fig. 3. E¡ects of sepsis on the photoa⁄nity labeling of L-adre-
noceptors in rat liver plasma membranes with [125I]ICYP diazir-
ine followed by SDS-PAGE. A depicts a representative autora-
diogram. Plasma membranes were reacted with [125I]ICYP
diazirine in the absence (lanes 1, 3, and 5) or presence (lanes 2,
4, and 6) of 10 WM alprenolol as described in Section 2. B
shows quantitative analyses of the incorporation of [125I]ICYP
diazirine into 64 kDa peptides. Vertical bars indicate S.E.M.
Numbers of experiments are shown in parentheses in each col-
umn. ES, early sepsis ; LS, late sepsis. Early and late sepsis re-
fer to measurements performed at 9 and 18 h, respectively, after
cecal ligation and puncture.
Fig. 2. E¡ects of sepsis on the density of L-adrenoceptors in
the light vesicles isolated from rat livers based on [3H]DHA
binding studies. [3H]DHA binding was performed as described
in Section 2. (A) Maximal binding capacity (Vmax); (B) Kd val-
ues. For symbols, abbreviations, and other details, see the
legend to Fig. 1.
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of LARs: a high-a⁄nity class of receptors coupled to
guanine nucleotide-binding stimulation protein (Gs)
and a low-a⁄nity class of receptors apparently un-
coupled from Gs. In contrast, the competitive bind-
ing studies for isoproterenol in the light vesicles pre-
pared from control rat demonstrate only low-a⁄nity
binding of isoproterenol with an IC50 value of
4U1037 M, and this binding was not modulated by
Gpp(NH)p. These data indicate that these light
vesicles are functionally and presumably physically
uncoupled from Gs, consistent with the notion that
light vesicles are the intracellular sites of surface re-
ceptors [26^28]. During the early and the late phases
of sepsis, the agonist displacement curves for
[3H]DHA binding in the plasma membranes and
the light vesicle fractions demonstrate only the low-
a⁄nity binding of isoproterenol with IC50 values of
1.5U1037^5.0U1037 M, and these bindings were not
modulated by Gpp(NH)p. These results reinforce the
¢ndings presented in Figs. 1 and 2 that LARs were
internalized from the surface membranes to the intra-
cellular sites in the rat liver during the early and the
late phases of sepsis.
Figs. 3 and 4 show the autoradiography of the
photoa⁄nity labeling of LARs using [125I]ICYP dia-
zirine in the plasma membranes and the light vesicles
prepared from control and septic rats. After photol-
ysis and SDS-PAGE, one single binding peptide with
a molecular mass of 64 kDa was labeled and visual-
ized in both membrane fractions of all three exper-
imental groups. The covalent incorporation of
[125I]ICYP diazirine into 64 kDa peptides was inhib-
ited by a speci¢c LAR antagonist, (3)-alprenolol,
indicating that the labeled peptides possess LAR spe-
ci¢city (lanes 2, 4 and 6 of Figs. 3 and 4). As shown
in Fig. 3, the binding for the labeled peptides in the
plasma membranes was decreased by 28% (P6 0.01)
and 46% (P6 0.01) during the early and the late
phases, respectively, of sepsis. As shown in Fig. 4,
the binding of the 64 kDa peptides in the light
vesicles was increased by 30% (P6 0.05) and 35%
(P6 0.05) during the early and the late phases, re-
spectively, of sepsis. These data using [125I]ICYP di-
azirine as a photoa⁄nity labeling probe, reinforce
the conclusion obtained from [3H]DHA binding
(Figs. 1 and 2) and Gpp(NH)p modulation (Table
1) studies that LARs in rat liver were internalized
from the surface membranes to the intracellular sites
during the progression of sepsis.
Table 2 depicts changes in the total number of
LAR binding sites (the sum of plasma membranes
and the light vesicles) in the rat liver during di¡erent
phases of sepsis. The total number of LAR binding
sites was decreased by 12% (P6 0.01) and 35%
(P6 0.01) during the early and the late phases, re-
spectively, of sepsis based on [3H]DHA binding stud-
ies. Similar results were obtained based on
[125I]ICYP diazirine labeling studies. These results
demonstrate that in addition to the internalization
from surface membranes to the intracellular sites,
LARs were progressively underexpressed during the
progression of sepsis.
4. Discussion
We have previously reported that K1ARs in the rat
liver were externalized from the light vesicles to plas-
ma membranes (overexpression) during the initial
hyperglycemic phase while they were internalized
from the surface membranes to the intracellular sites
(underexpression) during the late hypoglycemic
phase of sepsis [21,29]. In the current study, we
used the same sepsis model and identical procedures
for the isolation of plasma membranes and light
vesicles as of K1ARs [21,29] and found that LARs
were progressively internalized from the plasma
membranes to the light vesicles and, furthermore,
they were underexpressed during the early and the
late phases of sepsis. The internalization and the
underexpression of LARs in the rat liver during the
progression of sepsis were ¢rst revealed by [3H]DHA
binding assays (Figs. 1 and 2), an approach which
has been used extensively for the biochemical
characterization of LARs [25,28,30,31]. The results
obtained from [3H]DHA binding studies were subse-
quently veri¢ed by [125I]ICYP diazirine photoa⁄nity
labeling studies (Figs. 3 and 4), an avenue which has
been employed widely for the molecular clari¢cation
of LARs in various tissues [25,32]. In addition, the
observed internalization of LARs from surface mem-
branes to intracellular sites during the progression of
sepsis was reinforced by modulation studies using
Gpp(NH)p (Table 1) based on its unique property
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capable of shifting the agonist binding displacement
curve to the right [26,27,30,33].
Hepatic glucose metabolism is regulated by cate-
cholamines through mediation of KAR and LAR,
each coupled to a distinct intracellular second-mes-
senger system. Activation of KAR in the liver results
in an increase in hepatic glucose output to the circu-
lation through increases in inositol triphosphate and
cytosolic free Ca2 concentrations, stimulations of
glycogenolysis and gluconeogenesis, and inhibition
of glycogenesis [7]. Activation of LARs in the liver
enhances hepatic glucose release into the circulation
by increasing the generation of cAMP via G protein-
coupled adenylate cyclase pathway [5,6,8]. Thus, an
externalization/overexpression of KARs or LARs in-
creases plasma glucose concentrations while an inter-
nalization/underexpression decreases plasma glucose
levels. The fact that the internalization/underexpres-
sion of LARs as reported in the present study oc-
curred concomitantly with the externalization/over-
expression of K1ARs [21,29] during the early
hyperglycemic phase of sepsis, suggests that the in-
ternalization/underexpression of LARs may not play
a role in the altered plasma glucose concentrations
during the early phase of sepsis due to the overriding
e¡ect of K1AR externalization/overexpression. The
fact that the internalization/underexpression of
LARs took place simultaneously with the internaliza-
tion/underexpression of K1ARs during the late hypo-
glycemic phase of sepsis [21,29], suggests that the
internalization/underexpression of LARs provides
an additional additive e¡ect superimposed with the
internalization/underexpression of K1ARs in contri-
buting to the formation of hypoglycemia during the
late phase of sepsis. It is of interest to note that
changes in the dynamics of K1ARs during the pro-
gression of sepsis in the human liver [34] were found
to be identical to those in the rat liver [21]. It is
conceivable that LARs in human liver may undergo
similar changes as those in rat liver during sepsis.
Although hepatic glucose metabolism is predomi-
nately regulated by K1AR mediation in the rat liver
[6], studies with human subjects indicate that human
liver plasma membranes contain K1AR and L2AR in
almost equal proportions [35,36] and that stimula-
tion of glucose production in human liver by epi-
nephrine is mediated by both K- and L-adrenergic
mechanisms [37]. Thus, our ¢ndings that LARs
were internalized/underexpressed in the rat liver dur-
ing sepsis may have pathophysiological signi¢cance
in contributing to the understanding of the altered
hepatic glucose homeostasis in clinical sepsis.
The mechanism responsible for the internalization
of LARs from surface membranes to the intracellular
sites in the rat liver during the progression of sepsis is
not yet clear. Under physiological conditions, LARs
are in a dynamic life cycle involving receptor appear-
ance on, and disappearance from, the cell surface
[17^19]. Under certain pathological conditions, how-
ever, the distribution of LARs between the two sub-
cellular organelles can be altered [28,30,31], and the
intracellular redistribution of LARs has been associ-
ated with a process involving the altered phospho-
rylation of receptor proteins [17,38]. Although little
is known regarding the role of receptor phosphory-
lation in the regulation of hepatic glucose metabo-
lism in vivo, the role of the phosphorylation of LARs
in the control of organ function such as that in the
myocardium has been established by studies using
transgenic mice overexpressing the LAR gene, LAR
kinase (LARK), or LARK inhibitor [39^41]. Trans-
genic mice overexpressing LAR genes had an ele-
vated LAR density, an increased adenylate cyclase
activity, and an enhanced myocardial function
[39,40]. Transgenic mice overexpressing LARK dem-
onstrated damping of adenylate cyclase activity,
reduced functional coupling of LARs, and an attenu-
ation of isoproterenol-stimulated ventricular contrac-
tility while transgenic mice expressing LARK inhib-
itor displayed an enhanced cardiac contractility in
vivo [41]. These studies using transgenic animals il-
lustrate the important role of receptor phosphoryla-
tion/dephosphorylation in the modulation of organ
function in vivo. Since our previous works have dem-
onstrated that LARs were externalized during early
phase but internalized during late phase of sepsis in
the heart and that the externalization and the inter-
nalization were associated with a decrease and an
increase, respectively, of receptor phosphorylation
[25,42], it is possible that the internalization of
LARs in the liver during the progression of sepsis
is a result of an enhanced phosphorylation of recep-
tor proteins.
Recent advances on the molecular pathogenesis of
altered receptor function have indicated that pre-
translational regulation of receptor mRNA plays a
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pivotal role in the altered expression of LARs under
a variety of conditions. In heart failure, the density
of L1ARs was reduced and the reduction in L1AR
density was accompanied by a decrease in the
steady-state level of L1AR mRNA [43^45]. In cardiac
hypertrophy, there was a parallel decrease in L1AR
density and L1AR mRNA level [46]. In developing
liver, L2AR density was decreased and the decrease
in L2AR density paralleled with a decrease in the
steady-state level of L2AR mRNA [47]. Based on
these results, it is conceivable that the underexpres-
sion of LARs in the rat liver during the progression
of sepsis, as presented in this study, may be regulated
via transcriptional modi¢cation of L2AR gene tran-
scripts.
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